phenytoin has been researched along with clozapine in 33 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (9.09) | 18.7374 |
1990's | 4 (12.12) | 18.2507 |
2000's | 10 (30.30) | 29.6817 |
2010's | 16 (48.48) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hino, K; Karasawa, T; Masuda, Y; Nagai, Y; Oka, M; Uno, H | 1 |
Andrews, PR; Craik, DJ; Martin, JL | 1 |
Topliss, JG; Yoshida, F | 1 |
Faller, B; Wohnsland, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Gozalbes, R; Pineda-Lucena, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
Sen, S; Sinha, N | 1 |
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
Lee, KY; Nurok, D; Zlatkis, A | 1 |
Miller, DD | 1 |
Campbell, M; Cueva, JE | 1 |
Mol, CA; Schinkel, AH; van Deemter, L; Wagenaar, E | 1 |
Deckert, J; Retz, W; Supprian, T | 1 |
Antonetti, DA; Maines, LW; Smith, CD; Wolpert, EB | 1 |
Brightman, FA; Leahy, DE; Searle, GE; Thomas, S | 1 |
Gandelman-Marton, R; Klein, C; Rabey, JM; Theitler, J | 1 |
Chen, L; Chen, Z; Ding, F; Duan, S; Liu, Y; Nao, J; Wang, S; Wang, Y; Xu, C; Ying, X; Zhang, S; Zhong, K; Zhou, Y | 1 |
2 review(s) available for phenytoin and clozapine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II.
Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder; Carbamazepine; Child; Child Behavior Disorders; Child, Preschool; Clonidine; Clozapine; Depressive Disorder; Dose-Response Relationship, Drug; Feeding and Eating Disorders; Fluoxetine; Humans; Imipramine; Lithium; Mutism; Obsessive-Compulsive Disorder; Phenobarbital; Phenytoin; Phobic Disorders; Schizophrenia; Sleep Wake Disorders; Tranquilizing Agents | 1995 |
31 other study(ies) available for phenytoin and clozapine
Article | Year |
---|---|
A novel class of potential central nervous system agents. 3-Phenyl-2-(1-piperazinyl)-5H-1-benzazepines.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Body Temperature Regulation; Brain; Electroshock; Exploratory Behavior; Homovanillic Acid; Hypothermia; Indicators and Reagents; Male; Mice; Mice, Inbred Strains; Piperazines; Rats; Rats, Inbred Strains; Reserpine; Seizures; Structure-Activity Relationship | 1988 |
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
Topics: Alkanes; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Octanols; Permeability; Pharmaceutical Preparations; Solubility; Water | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Simultaneous determination of antiarrhythmia drugs by high-performance thin-layer chromatography.
Topics: Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Clozapine; Humans; Lidocaine; Phenytoin; Procainamide; Propranolol; Quinidine | 1978 |
Effect of phenytoin on plasma clozapine concentrations in two patients.
Topics: Adult; Clozapine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Phenytoin; Psychotic Disorders | 1991 |
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Brain; Cell Line; Clozapine; Diffusion; Domperidone; Epithelium; Flunitrazepam; Haloperidol; Humans; Kidney; Kinetics; Loperamide; Male; Mice; Mice, Inbred Strains; Ondansetron; Phenytoin; Recombinant Proteins; Structure-Activity Relationship; Swine; Tissue Distribution; Transfection | 1996 |
Clozapine-induced stuttering: epileptic brain activity?
Topics: Anticonvulsants; Antipsychotic Agents; Brain; Clozapine; Dose-Response Relationship, Drug; Electroencephalography; Epilepsy, Generalized; Female; Humans; Middle Aged; Phenytoin; Schizophrenia, Paranoid; Stuttering; Valproic Acid | 1999 |
Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells.
Topics: Animals; Anti-Inflammatory Agents; Anticonvulsants; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carbamazepine; Cattle; Cell Separation; Cells, Cultured; Cerebral Cortex; Clozapine; Endothelial Cells; Hydrocortisone; Paroxetine; Phenytoin; Rats; Retina; Selective Serotonin Reuptake Inhibitors | 2005 |
Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma.
Topics: Algorithms; Animals; Area Under Curve; Clozapine; Erythromycin; Half-Life; Injections, Intravenous; Metabolic Clearance Rate; Models, Animal; Models, Biological; Multivariate Analysis; Pentazocine; Phenytoin; Rats; Reproducibility of Results; Time Factors; Xenobiotics | 2006 |
Phenytoin intoxication in a clozapine-related prolonged seizure.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clozapine; Drug Interactions; Female; Humans; Phenytoin; Schizophrenia; Seizures | 2008 |
Subicular pyramidal neurons gate drug resistance in temporal lobe epilepsy.
Topics: Animals; Atrophy; Clozapine; Drug Resistant Epilepsy; Electric Stimulation; Epilepsy, Temporal Lobe; Female; Hippocampus; Humans; Male; Neural Inhibition; Optogenetics; Phenytoin; Pyramidal Cells; Rats; Sodium Channel Blockers; Sodium Channels | 2019 |